In brief
- MAPS responded to a report that Resilient Pharmaceuticals, formerly Lykos Therapeutics, had resubmitted its MDMA-for-PTSD application to the FDA.
- The release describes a reported resubmission without a new phase 3 trial; it does not itself verify every component of the submitted file.
- The move comes shortly after the FDA published its final guidance in July on how clinical research with psychedelics should be designed.
Two years after the FDA rejected MDMA-assisted therapy for post-traumatic stress disorder, MAPS described a report of resubmission without itself confirming regulatory acceptance. Resilient Pharmaceuticals, the successor to Lykos Therapeutics and the commercial arm of the MAPS organization, is the company named in the external report to which MAPS responded on August 10; MAPS states it has no active role in its drug-development program.
What the FDA requested and what has changed
MAPS describes the August 2024 FDA response as requesting more research on duration, safety and bias. Doblin interprets it as “not yet” and notes that pleasurable subjective effects were not systematically collected within safety assessment; these are not established therapeutic benefits. The original letter and the newly submitted file were not reviewed here.
A new guide and a different context
The resubmission arrives just after the FDA published, in July, the final version of its guidance Psychedelic Drugs: Considerations for Clinical Investigations, which finalizes the 2023 draft and provides recommendations for investigating these substances: on trial design and safety; this reading of its landing page does not certify every requirement in the document or establish a new law. Rick Doblin, founder of MAPS, summarized the sentiment of this second attempt by stating that they knew the FDA was not saying no, but rather “not yet.” This release does not verify an authorized trade name or an approval.
What it implies
Repeating an application without a new trial is a gamble. Resilient is confident that a reinforced dossier will be enough to convince the agency without having to recruit patients for years, but the history of the file, including an advisory panel that voted against it in 2024, makes it clear that the path is not yet clear. The FDA may request further information. For those who follow the field of psychedelics as a therapeutic pathway, the case illustrates the friction between regulatory requirements and the actual practice of substance-assisted support, an area where harm reduction has spent years documenting safety protocols regardless of whether an approved drug exists.
Source
- MAPS. MAPS Responds to Report of Progress for MDMA-assisted Therapy for PTSD with FDA. maps.org, August 10, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
